Viewing nowCombinationJadiplosing M Tablet 12.5/1000 mg (Empagliflozin, Metformin Hydrochloride)
Empagliflozin 12.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Youngpoong Pharmaceutical Co., Ltd.

MFDS item code 202302696 · Approved 2023.09.11 · Insurance code 661905790
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used to assist in blood glucose control for adults with type 2 diabetes by combining empagliflozin and metformin. It is most effective when taken together with dietary and exercise therapies and is suitable for patients whose blood glucose is not adequately controlled. Caution is required, especially for patients with cardiovascular diseases, so it is important to follow professional guidance. This medication helps improve blood glucose control, thus aiding in diabetes management.
The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients who cannot achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose of 10 mg) and their current metformin dose. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching from combination therapy with empagliflozin (total daily dose of 10 mg or 25 mg) and metformin to this medicine should take the same doses of empagliflozin and metformin as they were previously taking. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If a dose of this medicine is missed, take it as soon as you remember. However, do not take a double dose at one time; skip the missed dose in such cases. Special populations Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other symptoms that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should be initiated with the individual single-ingredient products empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Caution, item 1)). If renal function declines to a CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately (see Precautions for Use, 2. Patients Who Should Not Take This Medicine, item 2)). Older patients In patients aged 75 years or older, renal function and the risk of volume depletion should be taken into consideration.
This medication can cause a rare but serious metabolic side effect called severe lactic acidosis; therefore, it should not be administered to patients with impaired kidney function or those with serious infections, dehydration, or cardiovascular disease. The risk of hypoglycemia may increase when this medication is used with other diabetes medications, so patients taking insulin or sulfonylureas should closely monitor blood glucose changes. Patients with moderate to severe kidney impairment, those with acute kidney injury, patients with acute or chronic metabolic acidosis, patients with acute heart failure, pregnant or breastfeeding women, and specific patient groups should not use this medication. Regular monitoring of kidney function and serum creatinine levels is important before starting or during treatment with this medication to monitor kidney status. Patients at risk of fluid loss or elderly patients and those who are dehydrated should be especially cautious as this medication can lower blood pressure or cause dehydration. This medication may increase the risk of urinary tract infections and genital infections, so if infection symptoms appear, immediate consultation with healthcare professionals is necessary. Women who are pregnant or may become pregnant and those who are breastfeeding should not take this medication. Patients preparing for surgery should stop taking this medication 48 hours prior and resume after kidney function has returned to normal following surgery. Alcohol consumption may increase the risk of lactic acidosis, so excessive drinking should be avoided while using this medication. During treatment, closely observe blood glucose control status and any unusual symptoms, and consult a doctor immediately if any concerning symptoms arise. Safety and efficacy have not been established for children under 18 years of age, so this medication is not recommended. In case of overdose, serious side effects such as lactic acidosis may occur, so immediate treatment at a medical institution is necessary if suspected. This medication should be kept out of reach of children and stored in the original container to maintain quality.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent air or moisture from entering. It is important to maintain a storage temperature between 1 and 30 degrees Celsius at room temperature. This will help preserve the medication's effectiveness and safety for a longer period.
Biconvex oval film-coated tablet with a dark brownish purple color
30 tablets/bottle, 60 tablets/bottle, 10 tablets/box (10 tablets/PTP x 1), 60 tablets/box (10 tablets/PTP x 6)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Youngpoong Pharmaceutical Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.